This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2025. In addition, publicly available 2025 sales data of biosimilar antibodies and proteins as well as of new biologic modalities such as gene and cell therapy and RNA (antisense, siRNA) are included in the report. The report covers sales data of more than 400 biologic drugs.

Sales data were obtained from company disclosures up to March 05, 2026. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of January 29, 2026. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported (in few cases at constant exchange rates). Fiscal years different from the calendar year 2025 were re-calculated to calendar year 2025 sales.

The basis of the report form the individual sales data of products presented in groups:

• Non-TNF Anti-Inflammatory mAbs
• Cancer Antibodies
• Cardiometabolic Antibodies
• Ophthalmic Antibodies
• Insulin & Insulin Analogs
• Anti-TNF Antibodies
• Coagulation Factors
• Enzyme Replacement Therapy
• Neuromodulators (botulinumtoxins)
• Established Therapeutic Proteins
• Anti-Infective Antibodies
• Migraine Antibodies
• Other Proteins
• Biosimilar Antibodies & Proteins
• Gene, Cell & RNA Therapy

In the analytical part of the report, sales data from 2012 to 2025 are summarized for the class of products and their growth rates reported. Sales of established therapeutic proteins (erythropoietins, interferon, G-CSF, hGH and FSH) are presented for the period of 2012-2025.

Sales and growth rates of cancer antibodies were analyzed by subgroup:

• Anti-PD-1 & PD-L1 Antibodies (Abs)
• Other Immuno-Oncology (I-O) Abs
• Anti-Her2 Abs
• Anti-EGFR Abs
• Anti-VEGF/-R Abs
• Anti-CD20 Abs
• Other Cancer Abs

In addition, 2025 sales data of target-specific cancer antibodies were calculated.

Sales and growth rates of non-TNF anti-inflammatory antibodies were analyzed by therapeutic area:

• Dermatology
• Rheumatoid & Autoimmune
• Neuro-Inflammation
• Pulmonary & Respiratory
• Gastrointestinal

In addition, 2024 sales data of target-specific non-TNF anti-inflammatory antibodies were calculated.

To highlight commercial success of novel antibody drug modalities, development of sales and growth rates of antibody-drug conjugates and of bispecific antibodies are shown.

Company specific sales data for biosimilar antibodies and proteins are highlighted in a Table for the years 2020 to 2025 as far as published which allows a ranking of biosimilar companies based on total biosimilar revenues.

Total sales for novel biologic drug modalities, i.e. gene and cell therapy and RNA-based biologics (antisense, siRNA, PMOs), are presented and were considered if published.

Sales of innovator therapeutic antibodies and proteins were summarized per company and a ranking list was prepared for the TOP 30 companies regarding biologics sales in 2024.

The adoption of novel biologic modalities (gene & cell therapy, RNA) and of biosimilars with respect to sales volume by major pharmaceutical companies in the year 2025 is highlighted in relation to antibody and protein sales.

A total of 80 innovator therapeutic antibodies and proteins reached blockbuster status with 2025 sales exceeding US$ 1 bln which are listed in a ranking list of Blockbuster Biologics in 2025.